Blastoff! Virtual Incision’s surgical robot becomes the first sent to the International Space Station
In a giant leap for medtech-kind, a robotic surgery system is now en route to the International Space Station (ISS).
In a giant leap for medtech-kind, a robotic surgery system is now en route to the International Space Station (ISS).
Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money.
Catamaran Bio’s voyage is ending early, as the cell therapy biotech winds down operations and tries to find a new partner for its allogeneic solid tumor therapies.
An earlier version of this story was based on a conference call that was erroneously linked to today’s news release. Fierce Biotech has rewritten this story in its entirety as of 2:27 p.m. ET. The article was previously amended at 12:47 p.m. ET on Jan. 30, 2024, to clarify the number of people affected by the latest round of layoffs.
It’s early days, but Novo Nordisk’s oral, long-acting, GLP-1 and amylin weight loss drug was found to be safe and effective in a phase 1 trial, spurring plans to widen the development plan, Martin Holst Lange, EVP and head of development, told investors Wednesday.
Danaher took a major dip in its full-year earnings report, with revenues dropping more than 10% in 2023 despite better-than-expected results from the fourth quarter, following what it described as a “transformational year” for the company and an ongoing period of change that it expects will extend through at least the first half of 2024.
Some seven months after sounding the strategic search alarm, Avrobio will merge with Tectonic Therapeutic, with the latter’s GPCR-targeted meds now the combined company’s clinical focus.
GSK is moving to ease worries about the looming loss of exclusivity on its HIV blockbuster, setting out plans to launch at least 12 major products and deliver more than 38 billion pounds sterling ($48 billion) in risk-adjusted sales by 2031.
With an eye toward better matching its targeted therapeutics to the patients who will benefit most, Incyte has turned to Agilent Technologies to develop companion diagnostics for its drugs.
New data from Kura Oncology’s phase 1b trial show that the company’s oral leukemia treatment performed best on top of a standard-of-care combo regimen in newly diagnosed patients with specific mutations.